Intellectual Property Rights

Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd.

(2001) 5 SCC 73; 2001 (21) PTC 541 (SC)

Facts

Cadila Healthcare sold an anti-malarial drug under the mark FALCIGO.
The medicine contained artesunate and was used for treatment of falciparum malaria.
Cadila Pharmaceuticals later marketed another anti-malarial medicine under the mark FALCITAB.
Its product contained mefloquine hydrochloride.
Both companies had emerged from restructuring of the earlier Cadila group.
Cadila Healthcare sued for passing off.
It argued that:
FALCIGO and FALCITAB were phonetically similar;
both treated the same serious disease;
confusion could cause dangerous medical consequences.
Cadila Pharmaceuticals argued that:
“Falci” referred to falciparum malaria;
the drugs had different compositions, packaging and prices;
they were supplied mainly to hospitals and clinics.
The trial court and High Court refused an interim injunction.
The Supreme Court considered the governing principles.

Medicinal products require a stricter approach than ordinary consumer goods.
Confusion involving ordinary goods may produce economic loss.
Confusion involving medicines may cause:
serious injury;
adverse reactions;
treatment failure;
death.
Marks must be compared from the viewpoint of persons with average intelligence and imperfect recollection.
Relevant factors include:
nature of the marks;
visual, phonetic and conceptual resemblance;
nature and composition of goods;
similarity of purpose and performance;
class of purchasers;
purchaser education and care;
mode of purchase;
surrounding circumstances.
Prescription status does not eliminate risk because:
handwriting may be unclear;
pronunciation may vary;
pharmacists and medical staff may make mistakes;
linguistic diversity affects communication.

Both products were intended to treat falciparum malaria.
The shared prefix FALCI had a disease-related meaning and might therefore be weak by itself.
However, the marks still had to be compared as complete words:
FALCIGO;
FALCITAB.
The Court refused to make a final factual finding of deceptive similarity at the interim appellate stage because fuller evidence might be required.
It instead corrected the narrow approach adopted below.
The lower courts had placed too much confidence in:
different packaging;
hospital-only sale;
professional purchasers;
differences in active ingredients.
Doctors, pharmacists and hospital staff are not immune from confusion.
India’s multilingual conditions made phonetic confusion particularly important.
A prescription written or spoken in one accent might be misunderstood in another region.
The drugs contained different active ingredients.
A mistaken substitution could therefore be medically serious.
The Court emphasised preventive caution.
Where human health is involved, courts should prefer avoiding possible confusion rather than waiting for evidence of actual injury.
It also suggested that drug-control authorities should consider trademark searches before approving brand names.
Despite laying down a strict test, the Court did not finally grant the injunction.
It declined to interfere with the interlocutory orders and directed speedy trial.

The Supreme Court did not finally decide whether FALCIGO and FALCITAB were deceptively similar.
It directed the trial court to determine the suit using the stricter medicinal-product principles stated in the judgment.
The case established India’s leading multi-factor test for deceptive similarity, especially for medicines.
Use this case for: medicinal marks demand heightened caution because even a small possibility of confusion may endanger health, despite prescription controls or professional purchasers.